Finland's Bioretec Q1 revenue falls

Bioretec Oy

15/05/2026 07:10

Overview

Finland medical device maker's Q1 revenue fell 12.6% yr/yr, EPS remained negative

Adjusted sales margin rose to 70.1% from 56.7% after reporting methodology change

Company completed EUR 12.9 mln rights issue after the quarter to strengthen financial position

Outlook

Company says focus remains on commercial growth and advancing launch readiness for near-term pipeline

Bioretec says rights issue strengthens financial position for next phase of targeted growth

Company prioritizes disciplined execution, capital efficiency and innovation through RemeOs platform expansion for 2026–2028

Result Drivers

U.S. AND EUROPE GROWTH - Co said sales in the U.S. and Europe rose sharply due to new distribution channels and broader customer base

COMMERCIAL INVESTMENTS - Co said investments in leadership and commercial capabilities accelerated momentum, especially in the U.S.

REVENUE CONCENTRATION SHIFT - Co said activating new distribution channels and expanding direct customer base reduced concentration risk and improved revenue quality

Company press release: ID:nWkr6Hrnpt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 1.22 mln
Q1 EPS
-EUR 0.04
Q1 Net Income
-EUR 1.37 mln
Q1 EBITDA
-EUR 1.38 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Bioretec Oy is €0.02, about 32.4% above its May 13 closing price of €0.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)